Improving Blood CirculationNCT07446088
Electric Stimulation Home Use(CGM MEPC_2401) for Improving Blood Circulation
A study testing CERAGEM CELLTRON CIRCULATION CHAIR (CGM MEPC-2401) in people with Improving Blood Circulation and Blood Circulation, run by Ceragem Clinical Inc. at 1 site in South Korea.
Trial summary
This study is a single-center, open-label, exploratory clinical trial to evaluate the safety and efficacy of a statics electricity generator for improving blood circulation. Read more about this study
- Who is it for?
- Ages 19 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Improving Blood Circulation, Blood Circulation
- What is being tested?
- CERAGEM CELLTRON CIRCULATION CHAIR (CGM MEPC-2401)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteSouth Korea
- Study dates
- 1 Dec 2025to 30 Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged between 19 and 65 years
- Individuals with a BMI of 30.0 kg/m² or less
- Individuals without abnormal findings on hematology tests (CBC)
Who cannot join
- Patients with uncontrolled hypertension despite medication (defined as systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg measured at rest)
- Patients with medical conditions requiring the use of assistive devices (e.g., pacemaker, artificial joint, stent, prosthesis, etc.)
- Patients with seizure disorders or a history of loss of consciousness (e.g., epilepsy, acute febrile convulsions such as those associated with severe fever, etc.), or those at high risk of electric shock due to such conditions
- Patients with ventricular arrhythmias (e.g., ventricular tachycardia, history of coronary artery bypass surgery, etc.) and patients with neurological disorders (e.g., diabetic neuropathy, etc.)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Single-center, Open-label, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of a Statics Electricity Generator for Electric Stimulation Home Use(CGM MEPC_2401) for Improving Blood Circulation
This study is a single-center, open-label, exploratory clinical trial to evaluate the safety and efficacy of a statics electricity generator for improving blood circulation.
Read the detailed description
This clinical trial is conducted to evaluate the efficacy and safety of the personal electro-potential generator, CGM MEPC-2401, on the improvement of blood circulation in healthy adult subjects by applying the investigational medical device, the Ceragem Celtron Circulation Chair (CGM MEPC-2401).
- Conditions
- Improving Blood Circulation, Blood Circulation
- Being tested
- CERAGEM CELLTRON CIRCULATION CHAIR (CGM MEPC-2401)
- Keywords
- blood circulation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CERAGEM CELLTRON CIRCULATION CHAIR (CGM MEPC-2401)Device
Improving blood circulation device (Ceragem Celltron Circulation Chair)
| Study group | Role | What they receive |
|---|---|---|
| CGM MEPC-2401 | Experimental | Not described Receives: Device: CERAGEM CELLTRON CIRCULATION CHAIR (CGM MEPC-2401) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change and percent change in blood flow of the dorsal metacarpal vein
Change and percent change in blood flow of the dorsal metacarpal vein from baseline to immediately after a 30-minute application of the investigational device
Measured: from baseline to immediately after a 30-minute application of the investigational device
Secondary outcomes (3)
Change and percent change in capillary diameter assessed by capillary microscopy
Change and percent change in capillary diameter assessed by capillary microscopy from baseline to immediately after a 30-minute application of the investigational device (total duration: 30 minutes)
Measured: from baseline to immediately after a 30-minute application of the investigational device (total duration: 30 minutes)
Change and percent change in oxygen saturation (SpO₂)
Change and percent change in oxygen saturation (SpO₂) from baseline to immediately after a 30-minute application of the investigational device (total duration: 30 minutes)
Measured: from baseline to immediately after a 30-minute application of the investigational device (total duration: 30 minutes)
Change and percent change in blood zeta potential, cellular ATP levels, nitric oxide, membrane potential, and matrix metalloproteinases
Change and percent change in blood zeta potential, cellular ATP levels, nitric oxide, membrane potential, and matrix metalloproteinases from baseline to immediately after a 30-minute application of the investigational device (total duration: 30 minutes)
Measured: from baseline to immediately after a 30-minute application of the investigational device (total duration: 30 minutes)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2026
- Study start1 Dec 2025
- Primary completion30 Mar 2027 (estimated)
- Study completion30 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Improving Blood CirculationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ceragem Clinical Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Kwang Yong Shim, MD, Principal investigator, Wonju Severance Christian Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07446088
- Sponsor's protocol ID
- CG03-KR25BLC101
- Status last verified
- Oct 2026
- First submitted
- 2 Feb 2026
- Last updated
- 6 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-center, Open-label, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of a Statics Electricity Generator for Electric Stimulation Home Use(CGM MEPC_2401) for Improving Blood Circulation
- ClinicalTrials.gov ID
- NCT07446088
- Acronym / sponsor ID
- CG03-KR25BLC101
- Conditions
- Improving Blood Circulation, Blood Circulation
- Keywords
- blood circulation
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Ceragem Clinical Inc.Industry (pharma, biotech, devices)
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- 30 Mar 2027 (estimated)
- Study completion
- 30 Mar 2027 (estimated)
- First posted
- 3 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a single-center, open-label, exploratory clinical trial to evaluate the safety and efficacy of a statics electricity generator for improving blood circulation.
Detailed description
This clinical trial is conducted to evaluate the efficacy and safety of the personal electro-potential generator, CGM MEPC-2401, on the improvement of blood circulation in healthy adult subjects by applying the investigational medical device, the Ceragem Celtron Circulation Chair (CGM MEPC-2401).
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CGM MEPC-2401 | Experimental | Device: CERAGEM CELLTRON CIRCULATION CHAIR (CGM MEPC-2401) |
Who may qualify
- Ages
- 19 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults aged between 19 and 65 years
- Individuals with a BMI of 30.0 kg/m² or less
- Individuals without abnormal findings on hematology tests (CBC)
Key exclusion criteria (4 listed)
- Patients with uncontrolled hypertension despite medication (defined as systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg measured at rest)
- Patients with medical conditions requiring the use of assistive devices (e.g., pacemaker, artificial joint, stent, prosthesis, etc.)
- Patients with seizure disorders or a history of loss of consciousness (e.g., epilepsy, acute febrile convulsions such as those associated with severe fever, etc.), or those at high risk of electric shock due to such conditions
- Patients with ventricular arrhythmias (e.g., ventricular tachycardia, history of coronary artery bypass surgery, etc.) and patients with neurological disorders (e.g., diabetic neuropathy, etc.)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CERAGEM CELLTRON CIRCULATION CHAIR (CGM MEPC-2401)Improving blood circulation device (Ceragem Celltron Circulation Chair) | Device | CGM MEPC-2401 |
Primary outcome
Change and percent change in blood flow of the dorsal metacarpal vein
Time frame: from baseline to immediately after a 30-minute application of the investigational device
Change and percent change in blood flow of the dorsal metacarpal vein from baseline to immediately after a 30-minute application of the investigational device
3 secondary outcomes
Change and percent change in capillary diameter assessed by capillary microscopy
Time frame: from baseline to immediately after a 30-minute application of the investigational device (total duration: 30 minutes)
Change and percent change in oxygen saturation (SpO₂)
Time frame: from baseline to immediately after a 30-minute application of the investigational device (total duration: 30 minutes)
Change and percent change in blood zeta potential, cellular ATP levels, nitric oxide, membrane potential, and matrix metalloproteinases
Time frame: from baseline to immediately after a 30-minute application of the investigational device (total duration: 30 minutes)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Improving Blood Circulation
RecruitingPhase 1
IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease
Fontan Circulation
Active, not recruiting
Blood-Flow Restriction Exercise Following a Knee Replacement
Knee Injuries, Knee Osteoarthritis
Not yet recruitingPhase 4
Butylphthalide for Brain Edema After Endovascular Treatment
Acute Ischemic Stroke
Active, not recruiting
Effectiveness of Intermittent Vacuum Therapy Combined with Aerobic Exercise in Individuals with Diabetes Mellitus
Diabetes Mellitus
Active, not recruitingPhase 2
Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial
Cerebral Small Vessel Diseases, Stroke, Ischemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kwang Yong Shim, MD principal investigator
Wonju Severance Christian Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CERAGEM CELLTRON CIRCULATION CHAIR (CGM MEPC-2401) in people with Improving Blood Circulation and Blood Circulation, run by Ceragem Clinical Inc. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change and percent change in blood flow of the dorsal metacarpal vein (time frame: from baseline to immediately after a 30-minute application of the investigational device). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.